Latest price of amivantamab in 2025

Evantumumab (amivantamab) is a new targeted drug for the treatment of EGFR exon 20 insertion mutation non-small cell lung cancer . Its price differs significantly between domestic and overseas markets. At present, evantumumab is already on the market in China, but it has not yet been included in the medical insurance catalog, which means that patients need to bear all costs when using it. In the domestic market, the price of each box of 350mg is about RMB 7,000, while the price of the Hong Kong version of the original drug is slightly higher, about RMB 8,000. In comparison, the price of original drugs in the European market is higher, reaching about 20,000 yuan per box. The price varies due to exchange rate fluctuations and regional medical policies.

Currently, there are no generic versions of evantuzumab on the market, which will keep its price at a high level in the short term. Although the high drug price limits patient accessibility to a certain extent, it also reflects its research and development costs and clinical value as an innovative bispecific antibody drug. Globally, treatment options for NSCLC with EGFR exon 20 insertion mutations are limited, and evantumumab provides a new targeted approach that can meet the treatment needs of some refractory patients.

From an economic perspective, drug prices have a direct impact on patient compliance and long-term treatment planning. When prescribing evantumumab, clinicians need to rationally formulate a dosing regimen based on the patient's financial status, medical insurance policy, and drug accessibility. In addition, some patients can obtain drugs through clinical trials or international patient assistance programs to alleviate cost pressures.

In general, evantumumab is a high-priced innovative drug in both domestic and foreign markets, and it is still difficult to see significant price cuts or generic versions in the short term. With the accumulation of clinical experience and optimization of production processes in the future, its price may gradually stabilize, but within the foreseeable time, patients and medical institutions will still have to face high cost challenges.

Reference materials:https://www.rybrevant.com/